Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04704271 · ClinicalTrials.gov registry record · Phase 1
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
A Phase 1 study of Cannabis, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04704271: Recruiting Phase 1 study of Cannabis, sponsored by Yale University.
NCT04704271 is a Phase 1 study of Cannabis that is actively recruiting participants, run by Yale University. The registered enrollment target is 100 participants, roughly in line with the 107-participant average among 24 other Cannabis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04704271, a Phase 1 study of Cannabis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Primary Outcome
Subjective measure of THC induced "high"
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Inhaled THC
Study Locations (1)
Connecticut
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-10-09 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 1 |
What NCT04704271 shows while recruiting
NCT04704271 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 107-participant average among 24 other Cannabis trials with a reported enrollment target.
The record links to 1 condition, with Cannabis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04704271 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04704271 about?
NCT04704271 is a clinical study titled "Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II". The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
What is the current status of trial NCT04704271?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2019-10-09. Estimated completion is 2025-12-01.
What conditions does trial NCT04704271 study?
This clinical trial studies the following conditions: Cannabis.
What interventions are being tested in trial NCT04704271?
The interventions under investigation include: Placebo (DRUG), Inhaled THC (DRUG).
Who is sponsoring clinical trial NCT04704271?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04704271 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04704271's enrollment target sits among peer trials
100 6th of 24 higher than 18 of 24 other Cannabis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
ACTIVE NOT RECRUITING · Phase 1
-
Cannabinoids, Learning, and Memory
ACTIVE NOT RECRUITING · Phase 1
-
THC Memory & Reward Learning Pilot
ACTIVE NOT RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI